Spotting after menopause is not considered normal, but it is common, and the majority of cases turn out to be caused by benign conditions. Any vaginal bleeding that occurs a year or more after your last menstrual period counts as postmenopausal bleeding and should be evaluated by a healthcare provider. About 9% of women with postmenopausal bleeding are ultimately diagnosed with endometrial cancer, which means roughly 9 out of 10 cases have a noncancerous explanation.
Why It Happens: The Most Common Causes
The leading cause of postmenopausal spotting is vaginal atrophy. After menopause, dropping estrogen levels cause the vaginal lining to become thinner and drier. That fragile tissue bleeds more easily, sometimes from something as minor as friction during sex or a pelvic exam. This is extremely common and, while uncomfortable, is not dangerous.
Uterine polyps are the second major cause. These are small, noncancerous growths that develop in the lining of the uterus. They can cause light spotting or heavier bleeding and are typically straightforward to remove if needed.
Endometrial hyperplasia, an overgrowth of the uterine lining, is another possibility. This happens when the uterine lining is exposed to estrogen without the balancing effect of progesterone. The version without abnormal cell changes (called “without atypia”) is considered benign, with less than a 5% chance of progressing to cancer over 10 years. The version with abnormal cell changes is more serious and requires closer monitoring and treatment, as up to 50% of those cases may have or develop cancer.
Medications That Can Cause Spotting
If you recently started hormone replacement therapy (HRT), spotting in the first few months is expected. Irregular bleeding or spotting is common in the first four to six months of continuous combined HRT and typically resolves on its own. If you take sequential HRT, some withdrawal bleeding at the end of each progestogen cycle is also normal. Spotting that continues beyond six months, or that starts after a long stretch of no bleeding on HRT, is worth reporting to your provider.
Tamoxifen, a medication used in breast cancer treatment, is associated with roughly a fourfold higher risk of developing endometrial changes compared to nonusers. It can cause polyps, hyperplasia, and in some cases endometrial cancer, particularly with prolonged use beyond 48 months. Blood thinners (anticoagulants) can also trigger vaginal bleeding by making it harder for small blood vessels to clot normally.
Risk Factors Worth Knowing
Certain factors increase the likelihood of postmenopausal bleeding being caused by something more serious. Obesity is one of the most significant. Higher body weight is linked to greater estrogen production from fat tissue, which stimulates the uterine lining even after menopause. Diabetes, late menopause, and a history of polycystic ovarian syndrome also raise the risk of endometrial changes. If any of these apply to you, prompt evaluation of new spotting is especially important.
What the Evaluation Looks Like
Your provider will likely start with one of two tests: a transvaginal ultrasound or an endometrial biopsy. You don’t necessarily need both at the outset. The ultrasound uses a small probe inserted into the vagina to measure the thickness of the uterine lining. If the lining measures 4 millimeters or less, the chance of a serious problem is very low, and a biopsy may not be necessary.
If the lining is thicker than that, or if the ultrasound shows anything unusual like irregular texture or increased blood flow, your provider will likely recommend a biopsy. This involves taking a small tissue sample from the uterine lining, which is then examined under a microscope. The procedure is done in the office and takes a few minutes, though it can cause cramping.
If initial results come back normal but the spotting continues, additional testing is usually recommended. Persistent or recurrent bleeding after a negative workup should not be ignored.
How Each Cause Is Treated
Treatment depends entirely on what’s causing the bleeding. Vaginal atrophy is typically managed with topical estrogen, applied as a cream, ring, or tablet inserted into the vagina. This restores moisture and thickness to the vaginal walls and usually resolves the spotting within weeks.
Uterine polyps can often be left alone if they’re small and not causing significant symptoms, but they can also be removed through a minor procedure using a thin scope inserted through the cervix. Removal is more strongly recommended if you have additional risk factors like obesity, diabetes, or tamoxifen use.
Endometrial hyperplasia without abnormal cells is often treated with progestin therapy, which counteracts the estrogen stimulating the uterine lining. The atypical form, because of its stronger link to cancer, is more often treated with surgery to remove the uterus, though progestin therapy can reduce the progression risk by three to fivefold for those who want to avoid surgery.
If bleeding is related to HRT, your provider may adjust the dose or switch the type of hormone or delivery method, for example moving from tablets to patches. For bleeding caused by blood thinners, progestin therapy can help manage symptoms until the medication can be changed or stopped.
The Bottom Line on “Normal”
Spotting after menopause is never truly normal in the medical sense, meaning it always warrants investigation. But the odds are strongly in your favor. The vast majority of postmenopausal bleeding has a treatable, noncancerous cause. The reason providers take it seriously is that early evaluation catches the small percentage of serious cases when they’re most treatable. Even a single light episode of spotting, if it happens a year or more after your periods stopped, is reason enough to make an appointment.